Clinical data on rare Sulfamethoxazole crystalluria assessed by Fourier Transform Infrared Spectrophotometry

Vincent Castiglione, Etienne Cavalier, Romy Gadisseur

PII: S2352-3409(18)31399-4S0009-9120(18)30147-4
DOI: https://doi.org/10.1016/j.dib.2018.11.006
Reference: DIB3421

To appear in: Data in Brief

Received date: 17 May 2018
Revised date: 26 October 2018
Accepted date: 1 November 2018

Cite this article as: Vincent Castiglione, Etienne Cavalier and Romy Gadisseur, Clinical data on rare Sulfamethoxazole crystalluria assessed by Fourier Transform Infrared Spectrophotometry, Data in Brief, https://doi.org/10.1016/j.dib.2018.11.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Clinical data on rare Sulfamethoxazole crystalluria assessed by Fourier Transform Infrared Spectrophotometry

Vincent Castiglione¹, Etienne Cavalier, Romy Gadisseur

Clinical Chemistry Department, CHU de Liège, University of Liège, Belgium

Contact email: V.Castiglione@doct.uliege.be

Abstract

The data contained in this article are related to the article entitled “Case report: Uncommon Sulfamethoxazole Crystalluria” [1]. Sulfamethoxazole crystalluria is very rare and crystals identification is complex [2,3]. We identified seven patients with uncommon urine crystals that were composed of N-Acetyl-Sulfamethoxazole. Three of the patients developed an acute renal failure simultaneously to crystalluria. Hence, this article describes the method of crystals identification thanks to infrared spectroscopy. The relevant clinical data of patients, including medical history, drug dosage and urine parameters related to the crystalluria are presented.

Keywords: Sulfamethoxazole; crystalluria; drug; adverse effect; acute renal failure; infrared spectrophotometry; urine microscopy.

Specifications Table

<table>
<thead>
<tr>
<th>Subject area</th>
<th>Clinical biochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>More specific subject area</td>
<td>Drug crystalluria</td>
</tr>
<tr>
<td>Type of data</td>
<td>Figure, Table</td>
</tr>
<tr>
<td>How data was acquired</td>
<td>Crystals composition was determined by Fourier Transform Infrared Spectroscopy</td>
</tr>
<tr>
<td></td>
<td>Medical records of patients were retrospectively reviewed</td>
</tr>
<tr>
<td>Data format</td>
<td>Analyzed</td>
</tr>
<tr>
<td>Experimental factors</td>
<td>Urine sediment were dried after centrifugation</td>
</tr>
<tr>
<td>Experimental features</td>
<td>Residue was used to realize pellets for the FTIR analysis</td>
</tr>
<tr>
<td>Data source location</td>
<td>Liège, Belgium</td>
</tr>
<tr>
<td>Data accessibility</td>
<td>Data are with this article, and available as a Microsoft Excel Worksheet in supplementary data at Mendeley data <a href="https://data.mendeley.com/datasets/z9v9rznnynk/1/files/71777564-b6f1-4e3a-91fb-970813401ec8/TABLE1.EX.xlsx?dl=1">https://data.mendeley.com/datasets/z9v9rznnynk/1/files/71777564-b6f1-4e3a-91fb-970813401ec8/TABLE1.EX.xlsx?dl=1</a></td>
</tr>
</tbody>
</table>

¹ CHU de Liège - Sart Tilman, Clinical Chemistry - Prof. E. Cavalier, Route 52, Tour 2, +5, Porte 48, Avenue de l'Hopital 1, 4000 Liège (Belgium). Tel : +32.4366.83.53.
Value of the data

- The data report the largest case series of Sulfamethoxazole crystalluria.
- The description of the new crystal’s shapes will help to suspect Sulfamethoxazole crystalluria.
- The method describes how to identify uncommon urine crystals thanks to infrared spectroscopy.
- The data will help to identify risk factors and issues of Sulfamethoxazole crystalluria in future cases.

Data

Figure 1 illustrates the infrared spectra of N-Acetyl-Sulfamethoxazole reference (NASM) and of the dried residue from patient’s sample. The spectra of the dried residues of each patient included the absorbance peaks pattern of NASM. N-Acetyl-Sulfamethoxazole is the main metabolite of Sulfamethoxazole that can crystallize in urine [3–5].

Table 1, in supplementary data (https://data.mendeley.com/datasets/z9v9rznnyk/1/files/71777564-b6f1-4e3a-91fb-970813401ec8/TABLE1.EX.xlsx?dl=1), describes the medical records of patients, their drug dosage, urine parameters, blood creatinine levels and their outcomes. Note that four patients had diuretic medication. Lower cotrimoxazole doses were associated to crystals with rectangular shapes, while higher doses were associated to bigger and more irregular crystals.

Images of the crystals are available in the paper “Case report: Uncommon Sulfamethoxazole Crystalluria” [1], where the data are discussed.

**Fig. 1:** Fourier Transform Infrared spectra of (A) N-Acetyl-Sulfamethoxazole reference, and (B to H) dried urine residue from patient 1 to 7, respectively. The wavelengths of the main absorption peaks that are common between the samples and the reference are indicated.
Supplementary data
The supplementary table 1 is available at Mendeley data (https://data.mendeley.com/datasets/z9v9rznnnyk/1/files/71777564-b6f1-4e3a-91fb-970813401ec8/TABLE1.EX.xlsx?dl=1).

**Table 1:** Clinical parameter of patients with N-Acetyl-Sulfamethoxazole crystalluria
COPD, chronic obstructive pulmonary disease; NA, not available; iv, intra-venous; po, per os.

**Experimental Design, Materials and Methods**

More than 100 urine samples are analyzed daily at the University Hospital of Liège (Belgium). Between 2014 and 2017, we identified seven patients with NASM urinary crystals. The crystals were observed with the automated microscopy urine analyzer SediMAX° (Menarini, Milan, Italy). The crystals had unusual shapes, different from oxalate, uric acid, struvite or other common urine crystals. Crystals shapes included mushroom, flower, parallelepiped, truncated lozenges, thin rectangles and spheroids. In order to confirm their composition, we performed a Fourier Transform infrared spectrophotometry analysis adapted from Daudon et al [4]. The samples were stored at room temperature and analyzed within two hours. Samples were centrifuged for 5 minutes at 4000rpm. After centrifugation, the urine residue was collected on a glass and dried. The residue was then mixed with potassium bromide to make pellets that were analyzed thanks to an alpha-T infrared spectrophotometer (Bruker, Germany). The infrared spectra were then compared to spectra from a reference library (OPUS, Bruker Optics GmbH). When the pattern and wavelengths of the main peaks of the infrared spectra obtained from the samples were the same as NASM reference, it allowed identifying NASM crystalluria. The spectra also contained urea and proteins in various quantities due to other urine elements. Cotrimoxazole administration was then confirmed in all patients thanks to medical records.

We carefully reviewed medical records of each patient to check patient’s conditions, medications, urine parameters and creatinine measurement. Urine parameters at the crystalluria onset were assessed by SediMAX and AutionMAX (Menarini, Florence, Italy).

**Acknowledgements**

This study is in accordance with the Helsinki Declaration and with our local Ethical Committee. Declarations of interest: none

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**References**


